CMS Eyeing Test To Lower Part B Drug Payments Through ASP Formula Change
This article was originally published in The Pink Sheet Daily
Agency looks to its innovation center in lieu of legislation to curb spending; new budget plans cites $7.8bn in 10-year savings from rates set at ASP+3%.
You may also be interested in...
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.